Johnson & Johnson Family of Companies
1 Johnson & Johnson Plaza
New Brunswick
New Jersey
08933
United States
Tel: 732-524-0400
Fax: 732-524-3300
Website: http://www.jnj.com/
2096 articles with Johnson & Johnson Family of Companies
-
In 2018, the FDA approved 59 novel drugs, meaning approved new molecular entities. BioSpace analyzed new drug approvals from 2014 to 2018 to determine which companies were responsible for the most drug approvals in that period. Here’s a look.
-
Johnson & Johnson Recommends Rejection Of Below-Market "Mini-Tender" Offer By Peer & Peri LLC
1/11/2019
Johnson & Johnson received notice of an unsolicited "mini-tender" offer by Peer & Peri LLC (Peer & Peri) to purchase up to 30,000 shares of common stock of Johnson & Johnson, representing approximately 0.001% of the company's outstanding shares.
-
Johnson & Johnson Announces completion of Offer for Ci:z Holdings Co., Ltd.
1/11/2019
Johnson & Johnson today announced that the conditions to its public tender offer for all of the outstanding shares of Ci:z Holdings Co., Ltd. (TYO: 4924) (the "Company") not already held by Johnson & Johnson or its affiliates that was previously announced on October 23, 2018, have been satisfied and the offering period for the tender offer has expired.
-
As the Democratic-led House of Representatives begin to file a number of bills aimed at lowering the cost of prescription drugs in the United States, Johnson & Johnson has joined the ranks of pharma companies that started out the new year with a price hike.
-
Dr. Paul Janssen Award for Biomedical Research Issues 2019 Call for Nominations to Celebrate Champions of Science
1/10/2019
Nominations are now being accepted for the 2019 Dr. Paul Janssen Award for Biomedical Research.
-
With the JP Morgan Healthcare Conference ending today, it’s worth noting the word “healthcare” in the title, not “biopharma.” It’s not as if the biotech and pharmaceutical industry isn’t part of healthcare, but BioSpace’s reporting focuses on biopharma. Here’s a look at some of the more healthcar...
-
Ahead of the JP Morgan Healthcare Conference, Jamie Dimon, chief executive officer of JP Morgan Chase, hosted a private dinner for biopharma executives Sunday night. Although the dinner was private, apparently one of the hot topics of discussion was a company not represented at the party—Amazon.
-
Federal corporate tax cuts that were framed as a way to give a boost to employment across the United States have been more beneficial to companies and shareholders than the average worker or consumer, a new report issued by the advocacy group Americans for Tax Fairness shows.
-
Johnson & Johnson Innovation to Join NXT Biomedical Therapeutic Device Incubator to Accelerate Medical Device Innovation
1/8/2019
Most Promising Device Candidates to be Advanced to Center for Device Innovation at Texas Medical Center for Further Development
-
With the holidays over and the JP Morgan Healthcare Conference next week, companies were clearly revving their engines, ready to race into the new year. Here’s a roundup of some of the top deals that were announced today.
-
Under the terms of the deal, Janssen is paying Locus $20 million up front. Locus will be eligible for up to a total of $798 million in development and commercial milestones, as well as royalties on any product sales.
-
Johnson & Johnson Announces Quarterly Dividend for First Quarter 2019
1/2/2019
The dividend is payable on March 12, 2019 to shareholders of record at the close of business on February 26, 2019.
-
PwC recently came out with the latest version of their annual R&D spending report, and while there is a lot of interesting information to digest in this report, there are a few companies in particular that stand out within the field of biotechnology.
-
Johnson & Johnson to Participate in 37th Annual JP Morgan Health Care Conference
12/24/2018
Johnson & Johnson will participate in the 37th Annual JP Morgan Health Care Conference on Monday, Jan. 7th, at the Westin St. Francis in San Francisco.
-
In writing literally hundreds of stories this year, two BioSpace writers, Alex Keown and Mark Terry, found certain stories particularly intriguing or impactful. Some of those were such big topics that they were covered over a series of stories. Looking back at 2018, here are their Top 10.
-
As news continues about Johnson & Johnson’s talcum powder containing carcinogenic asbestos, more than 100 drug inspectors in India are seizing samples, characterized The Times of India. The company, however, downplays that description, suggesting that the samples are fairly routine.
-
Johnson & Johnson Announces $5 Billion Share Repurchase Program 2018
12/17/2018
Johnson & Johnson, announced that the Board of Directors has authorized the repurchase of up to $5 billion of the company's common stock.
-
More Woes Continue for J&J and Its Iconic Talc Product as Report Details a History of Contamination
12/17/2018
A Reuters analysis of company documents reveals that Johnson & Johnson knew about levels of asbestos contamination in its talc products, but did not report it to the FDA. -
Janssen Signs Results-Based Contract with Oklahoma Health Care Authority (OHCA) for its Long-Acting Injectable Schizophrenia Medicines
12/13/2018
With INVEGA SUSTENNA® and INVEGA TRINZA®, medicines shown to delay patient relapse, OHCA aims to reduce Medicaid costs, improve patient care
-
New Phase 3 data demonstrate superiority of TREMFYA® (guselkumab) vs Cosentyx® (secukinumab) in delivering PASI 90 responses in the treatment of moderate to severe plaque psoriasis at week 48
12/12/2018
84.5 percent of patients receiving TREMFYA achieved the primary endpoint of a PASI 90 response at week 48 compared with 70.0 percent of patients receiving Cosentyx